AstraZeneca quarterly net profit rises on strong cancer drug sales
This general view shows AstraZeneca signage on a building in Shanghai on Sept. 5, 2024. (AFP)
British pharmaceutical giant AstraZeneca July 27 said net profit rose in its second quarter, driven once again by strong growth in sales of its cancer drugs.
Profit after tax climbed more than two percent to $2.5 billion in the three months to the end of June, compared with the same period last year, AstraZeneca said in a results statement.
Total revenue increased six percent to $15.4 billion in the quarter, thanks to sustained strong demand for its cancer and rare disease medicines.
